Oral hypoglycemic agent. Prepn: Werner, Bell, J. Chem. Soc. 121, 1790 (1922); Shapiro et al., J. Am. Chem. Soc. 81, 3728 (1959). Use as antidiabetic: J. J. Sterne, US 3174901 (1965 to Jan Marcel Didier Aron-Samuel). Toxicity: Rx Bulletin 3, 25 (1972). Determn in plasma: S. AbuRuz et al., J. Chromatogr. B 798, 203 (2003). Clinical pharmacokinetics: G. T. Tucker et al., Br. J. Clin. Pharmacol. 12, 235 (1981). Review of pharmacology: L. S. Hermann, Diabete Metab. 5, 233-245 (1979). Metabolic effects and mechanism of action study: M. Stumvoll et al., N. Engl. J. Med. 333, 550 (1995). Review of efficacy in polycystic ovary syndrome: J. M. Lord et al., Br. Med. J. 327, 951-955 (2003); in type 2 diabetes mellitus: S. M. Setter et al., Clin. Ther. 25, 2991-3026 (2003).
Antidiabetic. In treatment of polycystic ovary syndrome.
Antidiabetic; Biguanides